Pharsight

1. Daybue patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11370755	ACADIA PHARMS INC	Compositions of trofinetide	Aug, 2040 (16 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9212204	ACADIA PHARMS INC	Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid	Jan, 2032 (8 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 10, 2030
New Chemical Entity Exclusivity (NCE)	Mar 10, 2028

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 2027-03-11

Market Authorisation Date: 10 March, 2023

Treatment: Treatment of rett syndrome or a symptom thereof

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
200MG/ML	SOLUTION;ORAL	Prescription

DAYBUE family patents

2. Nuplazid patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7923564	ACADIA PHARMS INC	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms	Sep, 2025 (1 year, 11 months from now)
US7732615	ACADIA PHARMS INC	N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms	Jun, 2028 (4 years from now)
US7601740	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Apr, 2030 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9765053	ACADIA PHARMS INC	Methods of treatment using selective 5-HT2A inverse agonists	Jul, 2022 (1 year, 2 months ago)
US10028944	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (3 months from now)
US8921393	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (3 months from now)
US8618130	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (3 months from now)
US9566271	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (3 months from now)
US7659285	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Aug, 2026 (2 years from now)
US10517860	ACADIA PHARMS INC	Combination of pimavanserin and cytochrome P450 modulators	Mar, 2037 (13 years from now)
US10953000	ACADIA PHARMS INC	Combination of pimavanserin and cytochrome P450 modulators	Mar, 2037 (13 years from now)
US10646480	ACADIA PHARMS INC	Formulations of pimavanserin	Aug, 2038 (14 years from now)
US11452721	ACADIA PHARMS INC	Formulations of pimavanserin	Aug, 2038 (14 years from now)
US10849891	ACADIA PHARMS INC	Formulations of pimavanserin	Aug, 2038 (14 years from now)
US10449185	ACADIA PHARMS INC	Formulations of pimavanserin	Aug, 2038 (14 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof; Treatment of psychosis or a symptom thereof; Tre...

Dosage: TABLET;ORAL